Quercetin-3 Sulfate: A Novel Inhibitor Targeting Helicobacter Pylori Revealed through Molecular Docking and Dynamic
Mohammed Baqur Al-Shuhaib1, Hayder O Hashim2, Mudher K Mohammed3
1Al-Qasim Green University.
Abstract:
Type II dehydroquinase (DHQase) is a pivotal enzyme in the synthesis of aromatic amino acids essential for Helicobacter pylori's survival. It possesses distinctive characteristics and exhibits limited sequence or structural similarity to other bacterial organisms. Molecular docking was employed to screen Middle Eastern medicinal plants to identify the most promising candidates for inhibiting DHQase with the highest affinity. Docking against DHQase was performed on 2,213 ligand conformers derived from 151 natural Middle Eastern medicinal plants. Ten hits with the most favorable docking scores were selected for subsequent ADMET assay analysis and molecular dynamic simulation. Of all of the top hits, quercetin-3 sulfate had the highest docking score. This compound adhered to the druglikeness roles and demonstrated no toxicity. MD simulations indicated that the quercetin-3 sulfate-DHQase complex exhibited higher levels of stabilized RMSD and higher values of stably contributed amino acid residues than other structures. This study underscores the novel inhibitory potential of quercetin 3-sulfate against DHQase, demonstrating the highest ligand affinity. This observation suggests the validity of quercetin 3-sulfate as a potent drug for combating H. pylori infection.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
05:23Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Gene Regulation in Microbial Communities: Quorum Sensing
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
